Prognostic index for adult patients with acute myeloid leukemia in first relapse.

PURPOSE The treatment of acute myeloid leukemia (AML) in first relapse is associated with unsatisfactory rates of complete responses that usually are short lived. Therefore, a clinically useful prognostic index can facilitate therapeutic decision making and evaluation of investigational treatment strategies at relapse of AML. PATIENTS AND METHODS A prognostic score is presented based on the multivariate analysis of 667 AML patients in first relapse among 1,540 newly diagnosed non-M3 AML patients (age 15 to 60 years) entered onto three successive Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research Collaborative Group trials. RESULTS Four clinically relevant parameters are included in this index (ie, length of relapse-free interval after first complete remission, cytogenetics at diagnosis, age at relapse, and whether previous stem-cell transplantation was performed). Using this stratification system, three risk groups were defined: a favorable prognostic group A (overall survival [OS] of 70% at 1 year and 46% at 5 years), an intermediate-risk group B (OS of 49% at 1 year and 18% at 5 years), and a poor-risk group C (OS of 16% at 1 year and 4% at 5 years). CONCLUSION The prognostic index estimates the outcome of AML patients in first relapse using four commonly applied clinical parameters and might identify patients who are candidates for salvage and investigational therapy.

[1]  W. Hiddemann,et al.  Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities , 2000, Leukemia.

[2]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[3]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[4]  C. Bloomfield,et al.  Prognostic factors at relapse for adults with acute myeloid leukemia , 1990, American journal of hematology.

[5]  S. T. Buckland,et al.  An Introduction to the Bootstrap. , 1994 .

[6]  M A Boogaerts,et al.  Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Tallman,et al.  Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia , 2000, Leukemia.

[8]  J. M. Bremner,et al.  Statistical Inference under Restrictions , 1973 .

[9]  R. Willemze,et al.  The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature , 2002, Leukemia & lymphoma.

[10]  H. Kantarjian,et al.  A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. , 1996, Blood.

[11]  E. Estey,et al.  Response to salvage therapy and survival after relapse in acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[13]  W. Hiddemann,et al.  Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. , 1990, Leukemia.

[14]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[15]  A. Keating,et al.  Results of Therapy for Acute Myeloid Leukemia in First Relapse. , 1991, Leukemia & lymphoma.

[16]  H. Kantarjian,et al.  The characteristics and outcome of patients with late relapse acute myelogenous leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[18]  K. Laczika,et al.  Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study , 1996, Annals of Hematology.

[19]  Augustin Ferrant,et al.  Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. , 2003, The New England journal of medicine.

[20]  R. Storb,et al.  Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Gray,et al.  A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial , 1999, British journal of haematology.

[22]  W. Hiddemann,et al.  Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy , 2002, Leukemia.

[23]  A. Burnett.  Acute myeloid leukemia: treatment of adults under 60 years. , 2002, Reviews in clinical and experimental hematology.

[24]  J. Kalbfleisch.  Statistical Inference Under Order Restrictions , 1975 .